Results 301 to 310 of about 887,639 (384)

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum‐Based Therapy

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland carcinoma (SGC). Although platinum‐based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after ...
Tomomi Sanomachi   +16 more
wiley   +1 more source

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Background In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1.
Alizée Simon   +6 more
wiley   +1 more source

Health‐Related Quality of Life in Patients With a Head and Neck Sarcoma: A Mixed‐Methods Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Patients with head and neck sarcomas (HNS) face unique health‐related quality of life (HRQoL) challenges due to its disease rarity. This study examined and identified the prevalence of generic‐ and location‐specific HRQoL issues.
E. Koffi   +25 more
wiley   +1 more source

Contributing Factors to Safety: What Hospitalized Patients Can Tell Us? A Cross‐Sectional Study

open access: yesThe International Journal of Health Planning and Management, EarlyView.
ABSTRACT Background Brazil has the second‐highest COVID‐19 mortality rate worldwide. While there are currently no guidelines for involving patients in their own safety, recognising patients' valuable feedback can be decisive for the safety and quality of healthcare.
Franciely Daiana Engel   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy